Vor Biopharma Inc. (VOR) - 10-K Filing Summary
Business Context and Reporting Period
Company: Vor Biopharma Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Vor Biopharma is a clinical-stage biotechnology company developing cell and genome engineering therapies for acute myeloid leukemia (AML). Its proprietary platform creates "shielded" hematopoietic stem cells (eHSCs) by removing therapeutic targets (e.g., CD33) to protect healthy cells from targeted therapies. The company's lead candidates are trem-cel (a shielded transplant) and VCAR33 (a donor-derived CAR-T therapy).
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(116,914) | $(117,863) |
| Operating Expenses | $(121,185) | $(126,036) |
| Research & Development (R&D) | $(93,310) | $(94,315) |
| General & Administrative (G&A) | $(27,875) | $(31,721) |
| Interest Income | $4,271 | $8,173 |
| Cash, Cash Equivalents & Marketable Securities | $91,900 | $137,175 |
| Accumulated Deficit | $(456,994) | $(340,080) |
Note: The company has no revenue and operates at a loss. Cash burn was approximately $99.7 million from operating activities in 2024.
Material Changes vs. Prior Period
- Net Loss: Decreased slightly by $0.9 million to $116.9 million, primarily due to a reduction in operating expenses.
- Operating Expenses: Decreased by $4.9 million. R&D expenses declined by $1.0 million due to reduced pre-clinical costs and license payments, offset by increased personnel costs. G&A expenses decreased by $3.8 million due to lower professional fees and stock-based compensation.
- Liquidity: Cash and marketable securities decreased by approximately $45.3 million year-over-year, driven by operating cash outflows and lower interest income ($3.9 million decrease).
- Capital Raise: In December 2024, the company completed a private placement raising $52.7 million in net proceeds, issuing 55.9 million shares and warrants for 69.8 million shares.
Guidance, Outlook, and Risks
Going Concern Warning: Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern for 12 months from the issuance date. Current cash resources are projected to fund operations only into the first quarter of 2026. Additional funding is required to advance clinical trials.
Clinical Progress:
- trem-cel (VBP101): Phase 1/2a trial data (25 patients) presented in late 2024 showed 100% engraftment and shielding of blood systems against Mylotarg toxicity. FDA agreed on a registrational trial design in December 2024.
- VCAR33 (VBP301): Phase 1/2 trial initiated; early data showed encouraging CAR-T expansion. Additional data expected in H1 2025.
- Outlook: The company plans to initiate a Phase 1 trial for the combined trem-cel+VCAR33 Treatment System in the second half of 2025.
Key Risks:
- Capital Needs: Dependence on raising additional equity or debt; failure to do so could force delays or elimination of R&D programs.
- Regulatory Uncertainty: Novel genome engineering technology faces uncertain regulatory pathways and potential delays.
- Manufacturing: Reliance on third-party manufacturers and the transition to in-house capabilities carries supply and quality risks.
- Intellectual Property: Heavy reliance on licensed IP from Columbia University and the NIH; termination of these licenses would be catastrophic.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "substantial doubt" going concern warning and the projection of funds lasting only into Q1 2026.
- Private Placement Terms: Review the specific terms of the December 2024 private placement, including warrant exercise prices ($0.838) and potential dilution impact.
- License Agreements: Confirm the status and milestone obligations of the exclusive licenses with Columbia University and the NIH (NCI).
- Clinical Trial Enrollment: Monitor enrollment rates for VBP101 and VBP301, as delays could significantly impact the projected 2025 data readouts.
- Stock-Based Compensation: Note the February 2025 stock option repricing (exercise price reduced to $1.34) and its potential impact on future compensation expenses.